Somebody deciding between semaglutide and tirzepatide is, whether they realize it or not, relying on a synthesis — a paper that gathered the trials, pooled them, and produced the comparison that everything downstream repeats. There are not many such papers, the best of them are genuinely good, and reading one carefully means reading both what it found and who was in a position to find it, which is a habit that also applies to the premium one of those two molecules commands on almost every price list.
What the review found
The largest recent example searched Medline and Embase to the end of January 2025 for randomized trials of obesity medications against placebo or an active comparator, and pooled 56 of them, enrolling 60,307 patients — 32,598 on a drug and 27,709 on placebo. [1] The primary endpoint was percentage of total body weight lost by the end of each study.
The trial counts are lopsided in a way the headline result hides. Orlistat, the oldest drug in the set, carries 22 of the 56 trials. Semaglutide has 14 and liraglutide 11. Tirzepatide, the one most often described as the strongest, rests on six. That is not a criticism of tirzepatide; it is a newer drug and its evidence base is younger. It does mean the comparison between the two headline molecules is built on fourteen trials against six, and a reader who takes the pooled estimates as equally settled is reading more confidence than the underlying literature supports.
Every drug in the set beat placebo on weight loss at P < 0.0001, and only semaglutide and tirzepatide passed 10% of total body weight. Both restored normoglycemia, produced remission of type 2 diabetes, and reduced heart failure hospitalization. Semaglutide alone showed a reduction in major adverse cardiovascular events and in knee osteoarthritis pain; tirzepatide alone showed remission of obstructive sleep apnea and of metabolic dysfunction-associated steatohepatitis. The authors conclude that the choice should be individualized, which is the correct conclusion and an unhelpful one for anybody standing in front of two prices — which is where the cost-benefit question leaves you as well.
The declaration
The review carries a competing-interests statement, as it should, and the statement is long. Twelve authors are listed. Ten of them declare a financial relationship with a company that manufactures one of the drugs under review — speaker fees, advisory board fees, consulting fees, research grants, and in one case a research award funded by a manufacturer’s charitable foundation, which is a weaker tie than the others and worth separating rather than lumping in. Two authors declare no conflicts relevant to the article.
Why that happens
Obesity pharmacology is a field with two dominant manufacturers, and the clinicians qualified to synthesize its trials are largely the same people those manufacturers recruit to advise, to speak, and to run the trials in the first place. Expertise and proximity grow together. The result is that a buyer looking for a comparison written by somebody with no commercial connection to either drug will find very few, and the ones they find will usually be smaller, older, or narrower than the one they skipped.
That is a structural problem and it has no clean consumer-side fix. What it does have is a reading practice: check the declaration, note which molecule the funding clusters around, and treat single-molecule superiority claims with more caution than shared findings. When two drugs both show an effect, the disclosure list matters less. When one shows an effect the other does not, it matters more — which is the situation with the cardiovascular result.
What this changes about a purchase
Very little, honestly, and saying so is more useful than manufacturing an implication. The pooled weight-loss estimates for both molecules are large, consistent across trials, and supported by placebo arms of tens of thousands of people. A declared speaker fee does not move a 10% figure that 14 randomized trials produced.
Where it should change something is confidence in the fine distinctions — the claim that one molecule is definitively better than the other, the ranking of secondary benefits, the extrapolation of a six-trial evidence base to a twelve-month purchase. Those are the claims that sell the more expensive option, and the price difference on this roster is real money. Buy the molecule your prescriber picks for a stated reason. Do not buy the one a comparison table ranked first without telling you who built the table.